| Severe Combined Immunodeficiency
Gamunex - C vs Xembify
Side-by-side clinical, coverage, and cost comparison for severe combined immunodeficiency.Deep comparison between: Gamunex-C vs Xembify with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsXembify has a higher rate of injection site reactions vs Gamunex-C based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Xembify but not Gamunex-C, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Gamunex-C
Xembify
At A Glance
IV infusion / SC injection
Every 3-4 weeks
Immune globulin
SC injection
Daily to every 2 weeks
Immune globulin replacement
Indications
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
- Congenital agammaglobulinemia
- Immune thrombocytopenic purpura
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
- Primary immune deficiency disorder
- Congenital agammaglobulinemia
- Common Variable Immunodeficiency
- X-linked agammaglobulinemia
- Wiskott-Aldrich Syndrome
- Severe Combined Immunodeficiency
Dosing
Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency, Congenital agammaglobulinemia IV: 300-600 mg/kg every 3-4 weeks; SC: initial weekly dose = prior monthly IGIV dose (g) x 1.37 divided by the number of weeks between IV doses, adjusted based on clinical response and IgG trough levels.
Immune thrombocytopenic purpura IV only: total dose of 2 g/kg given as 1 g/kg on two consecutive days or 0.4 g/kg on five consecutive days; do not administer subcutaneously.
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating IV loading dose: 2 g/kg over 2-4 consecutive days; maintenance: 1 g/kg every 3 weeks (or 0.5 g/kg on two consecutive days every 3 weeks).
Primary immune deficiency disorder, Congenital agammaglobulinemia, Common Variable Immunodeficiency, X-linked agammaglobulinemia, Wiskott-Aldrich Syndrome, Severe Combined Immunodeficiency SC infusion only; treatment-naive: 150 mg/kg/day loading dose for 5 consecutive days, then 150 mg/kg/week maintenance starting Day 8; switching from IVIG: begin 1 week after last IVIG, initial weekly dose (g) = prior IVIG dose (g) x 1.37 / number of weeks between IVIG doses; switching from IGSC: administer same weekly dose (g) as prior IGSC; doses may be adjusted for frequent (2-7 times/week) or biweekly administration.
Contraindications
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity reaction
- Previous anaphylactic or severe systemic reaction to human immune globulin
- IgA deficiency with antibodies against IgA and history of hypersensitivity to human immune globulin treatment
Adverse Reactions
Most common (>=5%) Headache, pyrexia, nausea, cough, rhinitis, pharyngitis, asthma, diarrhea, sinusitis, vomiting, ecchymosis, rash, arthralgia, chills, hypertension, asthenia, fatigue, local infusion site reactions (SC administration), upper respiratory tract infection, back pain, dyspepsia, abdominal pain.
Serious Exacerbation of autoimmune pure red cell aplasia, pulmonary embolism, hemolytic anemia.
Postmarketing Anaphylaxis, tachycardia, acute renal dysfunction/failure, acute respiratory distress syndrome, TRALI, pulmonary edema, bronchospasm, cardiac arrest, thromboembolism, vascular collapse, coma, seizures, aseptic meningitis, tremor, Stevens-Johnson syndrome, epidermolysis, erythema multiforme, pancytopenia, leukopenia, hemolytic anemia, hepatic dysfunction.
Most common (>=5%) Infusion site erythema, infusion site pain, infusion site swelling, infusion site bruising, infusion site nodule, infusion site pruritus, infusion site induration, infusion site scab, infusion site edema, cough, diarrhea
Postmarketing Anaphylactic reaction, hypersensitivity, aseptic meningitis, dizziness, paresthesia, tachycardia, hypotension, dyspnea, chest discomfort, injection site reactions, chills, fatigue, pain, tremor, laryngospasm
Pharmacology
GAMUNEX-C supplies a broad spectrum of opsonic and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins; the precise mechanisms of action in ITP and CIDP have not been fully elucidated.
XEMBIFY supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against bacterial, viral, parasitic, and mycoplasmal agents and their toxins, and contains antibodies capable of interacting with and altering the activity of immune system cells, though the full mechanism is not completely understood.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Gamunex-C
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (7/12) · Qty limit (0/12)
Xembify
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (5/12) · Qty limit (0/12)
UnitedHealthcare
Gamunex-C
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (1/8) · Qty limit (0/8)
Xembify
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Gamunex-C
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (3/3) · Qty limit (0/3)
Xembify
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Gamunex-C.
Cost estimate not availableAccessia Health: Primary Immune Deficiency - Private Insurance: Waitlist
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
Gamunex-CView full Gamunex-C profile
XembifyView full Xembify profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.